Johnson & Johnson said that a real-world study showed its single shot COVID-19 vaccine protects against breakthrough infections and hospitalizations for up to six months.
The study, sponsored by the vaccine developer, was conducted between January 1 and September 7 last year, before the Omicron variant was discovered. It is also yet to be peer-reviewed.
J&J said protection against infection from its single dose vaccine starts to wane only from the fourth month compared to the second month in the case of two-dose vaccines from rivals Pfizer Inc and BioNTech's as well as Moderna .
No waning of protection was found for ICU admissions for all the three vaccines, J&J said. The company said the study was carried out by collecting claims and laboratory data covering 168 million people.
At least 5 people killed in fire in Antwerp apartment block
Three people die in Mexico World Cup celebrations as fans crowd streets
US and Iran enter technical talks to secure peace deal, shipping restart
After Venezuela quakes, citizens lead rescues amid military theft accusations
Two dead after wildfire guts house in northern Greece
Afghanistan launches airstrikes on IS targets on border with Pakistan
Bangladesh warns of dengue surge as weather aids spread
Fourteen children killed in Pakistan after tutoring centre roof collapses
